Overview

A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma

Status:
Recruiting
Trial end date:
2025-08-09
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the overall minimal residual disease (MRD) negative rate of participants who receive JNJ-68284528.
Phase:
Phase 2
Details
Lead Sponsor:
Janssen Research & Development, LLC
Treatments:
Bortezomib
Daratumumab
Dexamethasone
Lenalidomide